Perceptive Advisors - CATABASIS PHARMACEUTICALS IN ownership

CATABASIS PHARMACEUTICALS IN's ticker is and the CUSIP is 14875P206. A total of 63 filers reported holding CATABASIS PHARMACEUTICALS IN in Q1 2021. The put-call ratio across all filers is 0.19 and the average weighting 0.0%.

Quarter-by-quarter ownership
Perceptive Advisors ownership history of CATABASIS PHARMACEUTICALS IN
ValueSharesWeighting
Q2 2021$32,438,000
+480.5%
15,374,370
+695.1%
0.21%
+197.2%
Q1 2021$5,588,0001,933,5510.07%
Other shareholders
CATABASIS PHARMACEUTICALS IN shareholders Q1 2021
NameSharesValueWeighting ↓
Soleus Capital Management, L.P. 775,000$2,240,0000.40%
SPHERA FUNDS MANAGEMENT LTD. 1,294,000$3,740,0000.29%
ArchPoint Investors 162,826$471,0000.13%
Ikarian Capital, LLC 852,998$2,464,0000.08%
Samsara BioCapital, LLC 150,000$434,0000.08%
Perceptive Advisors 1,933,551$5,588,0000.07%
Fairmount Funds Management LLC 53,166$154,0000.06%
Alyeska Investment Group, L.P. 1,124,623$3,250,0000.04%
Alyeska Investment Group, L.P. 731,303$2,113,0000.03%
Corient Capital Partners, LLC 103,523$299,0000.03%
View complete list of CATABASIS PHARMACEUTICALS IN shareholders